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Hematopoietic stem cells within the bone
marrow exist in a quiescent state. They can
differentiate and proliferate in response to he-
matopoietic stress (e.g., myelosuppression),
thereby ensuring a well-regulated supply of ma-
ture and immature hematopoietic cells within
the circulation. However, little is known about
how this stress response is coordinated. Here,
we show that plasminogen (Plg), a classical
fibrinolytic factor, is a key player in controlling
this stress response. Deletion of Plg in mice
prevented hematopoietic stem cells from enter-
ing the cell cycle and undergoing multilineage
differentiation after myelosuppression, leading
to the death of the mice. Activation of Plg by
administration of tissue-type plasminogen acti-
vator promoted matrix metalloproteinase-me-
diated release of Kit ligand from stromal cells,
thereby promoting hematopoietic progenitor
cell proliferation and differentiation. Thus, acti-
vation of the fibrinolytic cascade is a critical
step in regulating the hematopoietic stress
response.
INTRODUCTION
Hematopoiesis is initiated by multipotent hematopoietic
stem cells (HSCs). The blood-forming system is able to
respond efficiently to hematological stresses such as
bleeding, inflammation, or exposure to irradiation or cyto-
toxic agents by expanding the HSC population (Heissig
et al., 2005b). Thus, HSC proliferation and differentiation
must be highly adaptive to ensure both a durable produc-
tion of progenitor populations during steady-state hema-
topoiesis and extensive, stress-induced proliferation with-
out depletion of the stem cell pool. A major challenge in
stem cell biology is to elucidate the factors contributing
to this fine-tuned adaptation to stress or cell loss.
The bonemarrow (BM) is the primary hematopoietic site
in the adult. For example, the BM stromal compartment658 Cell Stem Cell 1, 658–670, December 2007 ª2007 Elsevierharbors extracellular matrix (ECM) and cytokines that are
capable of influencing self-renewal, proliferation, and
differentiation of hematopoietic stem and progenitor cells
(HSPCs).
The serine protease plasmin plays an important role in fi-
brinolysis and can degrade ECM molecules (Herren et al.,
2003). Plasminogen (Plg), its inactive proenzyme, can be
activated by tissue-type plasminogen activator (tPA), uro-
kinase-type plasminogen activator (uPA), and other serine
proteases. Mice with homozygously disrupted Plg genes
are predisposed to severe thrombosis and develop intra-
and extravascular fibrin deposition inmany tissues (Bugge
et al., 1995). During fibrinolysis, plasmin can participate in
the consecutive activation of matrix metalloproteinases
(MMPs) (Lijnen et al., 1998b; Liu et al., 2005).
In this study, we provide mechanistic data demonstrat-
ing that Plg/ mice exhibit defects in hematopoietic
reconstitution after myelosuppression, owing to a defect
in HSPC proliferation. The absence of Plg results in
impaired long-term survival after BM transplantation.
RESULTS
Plasmin Generation Is Required
for Hematopoietic Regeneration
We took advantage of mice with homozygously disrupted
Plg genes (Bugge et al., 1995) and amodel of stress hema-
topoiesis to investigate the role of Plg in hematopoiesis.
We stained BM sections for Plg during the early recovery
phase (2 or 3 days after myelosuppression) after chemo-
therapy and found positively stained areas along bone-
lining cells (Figure 1A). We therefore hypothesized that
plasmin(ogen) regulates hematopoietic reconstitution
after myelosuppression.
Myelosuppression induced by 5-fluorouracil (5-FU)
results in apoptosis of cycling HSPCs but does not affect
HSCs in G0 (Hattori et al., 2002). All Plg
/ mice receiving
5-FU succumbed by day 10 after 5-FU injection, whereas
Plg+/+ mice survived the 5-FU treatment (Figure 1B) and
exhibited recovery of white blood cells (WBCs) (Figure 1C),
platelets (see Figure S1A in the Supplemental Data avail-
able with this article online) and BM cells (Figure 1D).
During hematopoietic regeneration, quiescent (G0/G1)
stem cells enter the cell cycle and can differentiate.Inc.
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(Figure 1E) and immature megakaryocyte progenitors at
the 2N and 4N stage (Figure S1B) occurred in the Plg+/+
mice, but not in Plg/ mice. Hematopoietic recovery
was delayed in Plg/ mice as compared to Plg+/+ mice
(Figure 1F). Although the percentage of Sca-1+ cells in S
phase of the cell cycle was similar in Plg+/+ and Plg/
mice under steady-state conditions (Figure 1G), fewer
Sca-1+ cells shifted into S phase in Plg/ mice as com-
pared to wild-type (WT) cells upon myelosuppression.
Thus, cell-cycle transition and the stress-induced cell re-
generation did not occur in Plg-deficient mice. Treatment
with 5-FU did not result in death of mice singly deficient in
uPA (n = 5), tPA (n = 5), or urokinase plasminogen activator
receptor (uPAR) (n = 6) (data not shown). However, one out
of three uPA/tPA double-deficient mice died within the
first few days after 5-FU injection (data not shown).
Plg-Mediated Activation of MMPs
in the BM Promotes the Release of KitL
Plg activation can lead to activation of MMPs, especially
MMP-9 (Lijnen et al., 1998b). We found higher levels of
proMMP-2 and proMMP-9 but, more importantly, active
MMP-9 in supernatants of equal numbers of cultured
BM cells derived from Plg+/+ animals 5 and 10 days after
5-FU treatment, as compared to Plg/ mice (Figure 2A).
Levels of immunoreactive proMMP-9 were attenuated in
BM (Figure 2B), and less active MMP-9 was found in the
plasma of Plg/ mice treated with 5-FU (Figure 2C).
If plasmin activates MMPs, then plasma levels of KitL,
a cytokine implicated in hematopoietic regeneration that
can be regulated by MMP-9 (Heissig et al., 2002), should
be low in Plg/ mice after 5-FU treatment, as indeed
was the case (Figure 2D). We could implicate the lack
of hematopoietic recovery after myelosuppression to
impaired release of KitL in Plg/mice because daily injec-
tions of recombinant KitL partly restored the survival of
Plg/ mice (Figure 2E) and promoted BM cell recovery
(Figures 2F and 2G). Similarly, pretreatment of mice with
recombinant KitL restored BM cell-cycle progression in
Plg/ cells to levels observed in Plg+/+ cells (S, G2M
phase, Plg+/+ Sca-1+ cells 11.4% versus Plg/ Sca-1+
cells 9.5%, n = 3; not significant; 5 days after the start of
injection). Thus, the defective hematopoietic recovery in
Plg/mice can be attributed at least in part to the inability
to produce amounts of soluble KitL sufficient to induce
hematopoietic cell-cycle progression.
Administration of Recombinant tPA Promotes Plg
Accumulation and MMP Activation within the BM
Next, we investigated whether BM cells can produce Plg
or Plg activators. Plg mRNA was detectable in liver cells,
but not in freshly isolated BM lin or lin+ cells or in cul-
tured BM stroma (Figure 3A). tPA was strongly expressed
in BM stromal cells of both Plg+/+ and Plg/ mice and
cultured MS-5 stromal cells and was weakly expressed
in freshly isolated lin+ and lin cells of both Plg+/+ and
Plg/ mice. Immunoreactive tPA was found throughoutCellthe BM, including stromal cells, endothelial cells, and
some hematopoietic cells (Figure 3B).
We reasoned that tPA, through activation of Plg, indi-
rectly could activate MMPs in BM stromal cells. Active
MMP-9 and MMP-2 were detectable by zymography in
MS-5 (Figure 3C) and freshly isolated lin+ cells from
Plg+/+ animals (Figure 3D) incubated with recombinant
tPA. Immunoreactive Plg was detectable 1 hr after injec-
tion of recombinant tPA in close vicinity to sinusoidal BM
vessels (Figure 3E), while hematopoietic and stroma cells
throughout the BM of tPA-treated animals expressed
immunoreactive MMP-9 (Figure 3F).
tPA Treatment Augments the Release
of Soluble KitL
Since activation of MMP-9 modulates the c-Kit/KitL path-
way (Heissig et al., 2002), we assessed whether tPA
promotes KitL release, which could drive hematopoietic
regeneration. tPA treatment augmented the release of
KitL from MS-5 cells (Figure 3G) and primary BM stromal
cells (Figure 3H). Of importance, the tPA-mediated release
of KitL from stromal cells took place via MMP activation:
addition of a MMP inhibitor inhibited KitL release from
stromal cells. When MS-5 cells were treated with PAI-1,
the natural inhibitor of tPA, KitL release was lower than
in control supernatants.
If Plg is important for KitL release and tPA converts Plg
into plasmin, increased KitL plasma levels should be
found in tPA-treated animals, which indeed was the
case (Figure 3I). Similarly, KitL levels rose above baseline
levels after tPA treatment, even in Plg/ mice. Nonenzy-
matic mutant tPA has been reported to induce MMP-9
expression, suggesting that some actions of tPA are inde-
pendent of its proteolytic activity (Hu et al., 2006). When
MMP-deficient mice were injected with tPA, KitL plasma
levels did not rise, indicating that tPA-mediated KitL
release required MMP-9 activation (Figure 3I).
KitL in combination with other cytokines can push qui-
escent stem cells into cell cycle. More lin/Sca-1/c-Kit+
BM cells entered the S phase of the cell cycle in BM cells
of tPA-treated mice as compared to carrier-treated ani-
mals (Figure 3J). These data indicate that administration
of tPA leads to activation of MMPs, necessary for the
release of KitL from BM stromal cells. KitL in turn pushes
noncycling cells into cell cycle.
tPA Promotes Erythroid, Myelomonocytic,
and Megakaryocytic Cell Differentiation
Committed erythroid cells undergo several steps of differ-
entiation from erythroid progenitors, forming EPO-respon-
sive erythroblasts,whichdifferentiate ultimately to erythro-
cytes. Erythroid differentiation can be monitored by using
the markers CD71 and Ter119 (Socolovsky et al., 2001).
CD71 is expressed in hematopoietic cells including BFU-
Es, CFU-Es, and proerythroblasts, whereas Ter119 is
a late erythroid marker expressed in erythroblasts. Within
the BM of nontreated mice 0.44 ± 0.01 3 107 cells were
found within the Ter119hiCD71hi population (proerythro-
blast) and 0.11 ± 0.002 3 107 cells in the later stageStem Cell 1, 658–670, December 2007 ª2007 Elsevier Inc. 659
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Fibrinolytic System Regulates HematopoiesisFigure 1. Delayed Bone Marrow Cell Recovery in Plg/ Mice after Myelosuppression
(A–G) Plg+/+ (n = 12) and Plg/ mice (n = 12) received a single dose of the myelosuppressive agent 5-FU i.v.
(A) Immunohistochemical staining for Plg/plasmin (brown staining) in bone marrow (BM) sections from Plg+/+ and Plg/ mice treated with 5-FU.
Magnification 3100.
(B) Survival of 5-FU-treated mice was assessed daily.
(C) WBC counts were counted. Error bars represent standard error of the mean (SEM).
(D) Total number of BMMCs per femur was assessed. Error bars represent SEM.
(E) BM cells were stained for the myeloid markers CD11b-FITC and Gr-1-PE and analyzed by FACS (upper panel). Absolute numbers of CD11b+/
Gr-1+ BM cells per femur were calculated (lower panel). Error bars represent SEM.660 Cell Stem Cell 1, 658–670, December 2007 ª2007 Elsevier Inc.
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Fibrinolytic System Regulates HematopoiesisTer119hiCD71lo (erythroblast), as shown in Figure 3K. BM
cells of tPA-treatedanimals showedenhancederythroiddif-
ferentiation,with 0.33± 0.0073107 erythroblasts and0.24±
0.002 3 107 cells found within the Ter119hiCD71hi stage.
Granulocytic cells of adult mouse BM express CD11b
and high amounts of Gr-1. BM monocytic cells express
CD11b and little or no Gr-1 (Lagasse and Weissman,
1996). We assessed CD11b and Gr-1 expression in adult
BM with flow cytometry. The absolute number of
CD11b+Gr-1hi cells decreased in tPA-treated mice on
day 1 and to a lesser extent on day 3, whereas
CD11b+Gr-1lo cells increased as compared to untreated
animals (0.36 ± 0.007 versus 0.51 ± 0.01 3 107 on day 1).
The differentiation of megakaryocytes is characterized
by polyploidization and cytoplasmic maturation leading
to platelet production. The percentage of polyploid mega-
karyocytese of 32 and 64N ploidy increased in tPA-treated
mice as compared to controls (Figure S1C). These data
indicate that administration of tPA promotes erythroid,
myelomonocytic, and megakaryocytic cell differentiation
in vivo. But further studies will be needed to understand
the underlying mechanism.
tPA-Mediated HSPC Expansion Requires
the Presence of KitL
To assess whether tPA can act as a hematopoietic cyto-
kine, we evaluated HSPC expansion both in vitro and
in vivo. tPA administration in vivo augmented the number
of BM cells in WT controls, but this was attenuated in both
Plg-deficient and MMP-9-deficient mice (Figure 4A). tPA
increased the number of spleen colony-forming units
day 8 (CFU-Sd8, Figure 4B), of long-term culture-initiating
cells (LTC-IC, Figure 4C), and of the c-Kit+/Sca-1+/lin
(KSL) cell fraction in BM cells of treated animals
(Figure 4D). Long-term injection of tPA kept BM cell num-
bers persistently elevated above steady-state values
(Figure 4E). These data indicate that tPA, through activa-
tion of Plg, influences progenitor cell proliferation.
KitL can expand hematopoietic CFCs of multiple types
in the BM (Andrews et al., 1992) and increase marrow cel-
lularity. To test if tPA-mediated hematopoietic cell prolifer-
ation is dependent onKitL in vivo,we treatedKitL-deficient
Sl/Sld mice andWBB6F1+/+ control micewith tPA. BMcel-
lularity (Figure 4F) and the number of immature CFU-Sd8
progenitor cells (Figure 4G) increased in WBB6F1+/+
animals by day 2 after tPA injections, but not in Sl/Sld
mice. These studies show that tPA-mediated hematopoi-
etic cell proliferation requires the presence of KitL.
Plg-Deficient Mice Do Not Have
an Intrinsic Hematopoietic Stem Cell Defect
We noticed that, in the steady state, Plg/ mice showed
a reduced number of immature cells including LTC-IC,
CFU-Sd8, and Sca-1+/c-Kit+ cells in BM as compared
to controls (Figures 4B–4D). The percentage of side
population (SP) cells within the BM was lower in Plg/Cell Sas compared to Plg+/+ mice (0.018% ± 0.001% versus
0.051% ± 0.005%; n = 9, p < 0.0001). Even though LTC-
IC, CFUSd8, and SP cells show enrichment for HSCs,
they still contain a significant number of progenitor cells.
For example, the SP cell fraction is enriched between
1000-fold and 3000-fold for HSCs (Goodell et al., 1996).
To date, transplantation assays are still regarded as the
most stringent assay for the quantification of stem cells.
To ensure that the decreased number of progenitor cells
was due to extrinsic factors (e.g., the lack of KitL within
the hematopoietic microenvironment) rather than an
intrinsic stem cell defect, we performed competitive repo-
pulation experiments with the congenic CD45.1/CD45.2
alleles to distinguish donor and competitor cells. We
transplanted various cell numbers of BM mononuclear
cells (BMMCs) from Plg+/+ and Plg/ mice into congenic
CD45.1 lethally irradiated recipient mice. A minimum of
53 104 transplanted cells of either Plg+/+ and Plg/ cells
were necessary to detect donor cells in the PB cell fraction
after 90 days. Plg/ cells showed identical engraftment in
WT CD45.1 recipients (Figure 4H). Transplantation of
CD45.2+ KSL cells (10, 50, 100) from Plg+/+ and Plg/
mice together with CD45.1 competitor cells resulted in
identical three-lineage hematopoietic engraftment
(Figure S1D) when analyzed 7 months after transplanta-
tion. The frequency of competitive repopulation units
(CRUs) in Plg+/+ and Plg/ KSL cells was identical
(Figure S1E). These data indicate that Plg-deficient mice
do not have a functional HSC but rather a progenitor cell
defect.
Plg and MMP-9 Are Necessary
for tPA-Mediated BM Reconstitution
To address the question of whether tPA-mediated hema-
topoiesis requires Plg and/or MMP-9, we treated Plg- and
MMP-deficient with 5-FU on day 0 followed by daily injec-
tionswith or without recombinant tPA. tPA did not improve
survival (Figure 5A), recovery of WBC (Figure 5B), or the
number of BM cells (Figure 5C) in Plg/mice. Of interest,
stronger Plg/plasmin staining was detectable by immuno-
histochemistry after the administration of recombinant
tPA into Plg+/+ mice in BM areas close to the bone
(Figure 5D).
To elucidate why tPA-treated Plg+/+ mice showed faster
BM recovery and higher leukocyte counts, we examined
BM cell myelograms. In myelogram analysis, percentages
of late myeloid cells, such as neutrophils and metamyelo-
cytes, increased in tPA-treated mice as compared with
nontreated littermates (Figure 5E). Similarly, the number
of erythroblasts increased at the expense of the more im-
mature proerythroblasts (Figure 5F). tPA did not promote
cell differentiation in Plg/ mice (data not shown).
Similarly, in 5-FU-treatedMMP-9-deficient mice, the re-
covery of BM cells (Figure 5G) or WBCs (Figure 5H) was
delayed, and death after 5-FU (Figure 5I) could not be res-
cued/prevented using daily injections of recombinant tPA.(F) H&E staining of BM sections after 5-FU treatment. Arrows depict hematopoietic cells. Magnification 3200.
(G) DNA content of Sca-1+ BM cells was determined after 5-FU treatment (n = 3 per group and time point). *p < 0.05.tem Cell 1, 658–670, December 2007 ª2007 Elsevier Inc. 661
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Fibrinolytic System Regulates HematopoiesisFigure 2. MMP Activation and KitL Release Are Impaired in Plg/Mice after Myelosuppression, Resulting in BMRecovery Failure
(A–D) Plg+/+ and Plg/mice were injected with a single dose of 5-FU i.v. (A) BM cells (three mice per time point) were cultured in serum-free medium
overnight. Cell supernatants were assayed for proMMP-9 (103 kDa), active MMP-9 (86 kDa), proMMP-2 (72 kDa), and active MMP-2 (62 kDa) by
gelatin zymography. Error bars represent standard deviation. (B) Immunohistochemistry of BM sections 9 days after 5-FU injection for proMMP-9
with positive staining in the BM stromal compartment of Plg+/+, but less in the BM stromal compartment of Plg/ mice. Magnification 3200.
(C and D) Plasma obtained from peripheral blood (PB) was assayed for active MMP-9 (C) or KitL (D) by ELISA (p < 0.05). Error bars represent SEM.
(E–G) Plg+/+ and Plg/ mice were left untreated (n = 8) or received a single injection of 5-FU i.v. with/without daily i.v. injections of recombinant
KitL (n = 6). (E) Survival of treated animals was determined daily. (F) Total number of BM cells per femur was assessed. Error bars represent SEM.
(G) H&E staining of BM sections 10 days after 5-FU treatment. Magnification 3200. *p < 0.05.662 Cell Stem Cell 1, 658–670, December 2007 ª2007 Elsevier Inc.
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Fibrinolytic System Regulates HematopoiesisFigure 3. tPA-Mediated MMP Activation Releases KitL from Stromal Cells
(A) RT-PCR for tPA and Plg in liver (sample 1; positive control for Plg), 4-week-old BM stroma of Plg+/+ mice (sample 2) and of Plg/mice (sample 3),
MS-5 cells (sample 4), freshly isolated BM-derived lin cells from Plg+/+ mice (sample 5), or Plg/ mice (sample 6), as well as freshly isolated
BM-derived lin+ cells from Plg+/+ mice (sample 7) or Plg/ mice (sample 8). Agarose gel of one representative experiment.
(B) Immunohistochemistry for tPA in BM sections of Plg+/+ mice under steady-state conditions (magnification 3200). (Insert) Vessel stained positive
for tPA.
(C–F) MS-5 cells (C) or lin+ BMMCs from Plg+/+ mice (D) were cultured overnight with/without tPA under serum-free conditions. Supernatants were
analyzed by zymography for MMP-2 and MMP-9. Error bars represent standard deviation. Immunohistochemistry for Plg (E) and MMP-9 (F) in BM
sections of Plg+/+ mice 3 days after starting tPA treatment (magnification 3200).
(G and H) Confluent MS-5 stromal cells (G) or Plg+/+ primary BM stroma cells (H) were cultured overnight in serum-free medium (n = 3) in the presence
of recombinant tPA, recombinant PAI-1, and MPI (CGS 27023A) with or without tPA. Supernatants were collected and analyzed for KitL by ELISA
(n = 3, p < 0.05). Error bars represent SEM.
(I–K) Plg/ and MMP-9/ mice and littermate mice were injected with a single dose of tPA or PBS daily from day 0–2 i.p. (I) Blood was drawn after
tPA administration as indicated. Plasma samples were analyzed for KitL by ELISA (n = 6; ELISA was performed twice). Error bars represent SEM. (J)
BMcells were collected on day 0 and day 2. Sca-1/ c-Kit+/Lin (KSL) cells were costainedwith PI. Cell-cycle analysiswas performed on KSL cells (n =
3). (K) BMMCs of tPA- and non-tPA-treated animals (n = 3) were incubated with anti-Ter119 and anti-CD71 antibodies. Proerythroblasts stained pos-
itive for CD71hiTer119hi, whereas erythroblasts stained positive for CD71loTer119hi. Granulocytic cells are positive for CD11b and Gr-1, whereas BM-
derived monocytic cells showed positive staining for CD11b and expressed little or no Gr-1. Absolute numbers are given. Error bars represent SEM.Death occurred in about 70% of MMP-9/ mice. Thus,
the effect of tPA on hematopoietic reconstitution after
myelosuppression requires the presence of both Plg and
MMP-9 and possibly other MMPs.
Fibrinolytic Factors Expressed within
the BM Promote Hematopoietic Cell Proliferation
and Differentiation
To elucidate whether the observed tPA effects on hemato-
poietic cells were mediated directly by tPA or indirectly,
e.g., via BM stromal cells, we examined the effect of tPACell Son hematopoietic cell expansion in vitro. tPA improved
proliferation of lin cells in stromal-cell-based cultures
(MS-5 feeder layer) (Figure 6A), but not in the absence of
a feeder layer (Figures S1F and S1G). In synergy, tPA
and KitL expanded the number of progenitors in stromal-
cell-based cultures. Comparable numbers of progenitor
colonies emerged in cultures set up with Plg+/+ or Plg/
lin cells (Figure 6A).
If c-Kit/KitL signaling following tPA treatment promotes
hematopoietic cell proliferation, blocking the signaling
should prevent tPA-induced progenitor proliferation.tem Cell 1, 658–670, December 2007 ª2007 Elsevier Inc. 663
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Fibrinolytic System Regulates HematopoiesisFigure 4. tPA Promotes HSPC Proliferation in KitL-Competent Mice
(A) Plg-deficient, MMP-9-deficient, and littermate mice were injected with recombinant tPA i.p. from day 0–2 (short-term effect), and BM cells were
counted. BMcells of Plg+/+ and Plg/ cells were analyzed in aCFU-S assay ([B], n = 9), LTC-IC assay ([C], n = 9), and by FACS for the presence of KSL
cells ([D], n = 9). (E) Plg+/+ and Plg/ mice were injected with recombinant tPA from day 0–5 (long-term effect), and BM cells were counted (n = 9).
(F and G) Sl/Sld and WBB6F1 mice were treated with/without tPA (n = 5). BM cell numbers per femur (F) and the number of CFU-S were determined
(G). (H) Mouse PB cell donor contribution transplantation of BM cells from Plg+/+ and Plg/ BM CD45.2+ cells at limiting cell dilutions into CD45.1+
recipient mice (n = 9 per cell concentration); *p < 0.05. Error bars represent SEM.664 Cell Stem Cell 1, 658–670, December 2007 ª2007 Elsevier Inc.
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Fibrinolytic System Regulates HematopoiesisFigure 5. tPA-Mediated BM Reconstitution Requires Both Plg and MMP Activation
Plg+/+ and Plg/ mice (A–F) and MMP-9+/+ and MMP-9/ mice (G–I) were injected with a single dose of 5-FU followed by daily injections with
recombinant tPA or carrier. (A) Survival was assessed daily in Plg+/+ (n = 9 per group) and Plg/ mice (n = 8 per group). WBC counts (B) and BM
cell numbers per femur (C) were determined. Error bars represent SEM. (D) BM sections of Plg+/+ mice coinjection with or without tPA were stained
for Plg 2 days after 5-FU treatment (brown staining). Plg staining was found along bone-lining cells. (E and F) BM myelogram was performed.
Percentage of myeloid (E) and erythroid (F) BM cells are given. (G–I) BM cell numbers per femur (G), WBC counts (H), and survival (I) were assessed
in MMP-9+/+ and MMP-9/ mice (n = 12). *p < 0.05. (E–H) Error bars represent SEM.Indeed, addition of neutralizing antibodies against c-Kit
and/or KitL prevented the tPA-mediated generation of
CFU-Cs from lin cells in stromal-cell-based cultures
(Figure 6B). Likewise, addition of PAI-1, the natural inhib-
itor of tPA to these cultures, abolished tPA-mediated
CFU-C formation. Confirming our in vivo data, addition
of a synthetic MPI completely blocked progenitor produc-
tion and prevented tPA-mediated progenitor expansion.
These data imply that tPA can modulate progenitor cell
expansion by promoting the release of KitL.
tPA affected hematopoietic cells only in the presence of
stromal cells. So do Plg-deficient mice have a stromal cell
defect causing the observed hematopoietic phenotype?
When CD45.1 donor cells were transplanted into Plg+/+
or Plg/ recipients, donor cell contribution to PB leuko-
cytes 80 days after transplantation was lower in Plg/
than in Plg+/+ recipient mice (Figure 6C). This was espe-
cially apparent at limiting cell dilutions and correlated
with decreased mouse survival at 80 days after transplan-
tation of CD45.1 donor cells in Plg/ recipient mice
(Figure 6D). Fewer donor cells were necessary to promoteCell Ssurvival in Plg+/+ recipient mice (Figure 6E). These data im-
ply that the absence of Plg in the BM is responsible for the
reduced hematopoietic cell proliferation in Plg/ mice.
To overcome the problem of reduced cell proliferation in
a Plg-deficient microenvironment, we transplanted very
high numbers of BM cells (2 3 107 cells/mouse) from
Plg/ or Plg+/+ mice into lethally irradiated Plg/ or
Plg+/+ mice. Under these conditions, all mice survived
and showed engraftment after 4 weeks (WBC counts of
WT cells transplanted into WT mice 7933 ± 945/mL blood;
KO cells into WT mice 7133 ± 1815 ml blood; WT cells into
KO mice 6400 ± 1697 ml blood; KO cells into KO mice
7700 ± 1556/mL blood). Then, chimeric mice were treated
with the myelosuppressive agent 5-FU. Plg-deficient mice
transplanted with either Plg+/+ or Plg/ BM donor cells
succumbedwithin the first 2 weeks after induction of mye-
losuppression (Figure 6F; n = 9 per group). In contrast, all
Plg WT mice transplanted with either Plg+/+ or Plg/ BM
donor cells survived (n = 9 per group), emphasizing a criti-
cal role for Plg in the nonhematopoietic BM compartment.
We then asked if the impaired survival and cell proliferationtem Cell 1, 658–670, December 2007 ª2007 Elsevier Inc. 665
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Fibrinolytic System Regulates HematopoiesisFigure 6. Plg-Deficient Mice Have a Defective BM Stromal Compartment due to Impaired Release of KitL
(A) Lin cells from Plg+/+ and Plg/ mice were cultured in the presence or absence of tPA with or without KitL on MS-5 stromal cells. After 7 days,
cells were harvested and subjected into a progenitor assay (n = 6).
(B) Lin cells from Plg+/+ mice were cultured on confluent MS-5 stromal cells in serum-free medium (n = 3). Recombinant tPA, recombinant PAI-1,
antibodies against c-Kit or KitL, or a matrix metalloproteinase inhibitor (MPI; CGS 27023A) was added to the cultures for 5 days. Cells were collected
and subjected to a progenitor assay.
(C–E) BM cells from CD45.1 congenic donor mice were transplanted at limiting cell dilutions into lethally irradiated Plg+/+ or Plg/ CD45.2+ recipient
mice (n = 6). (C) Mouse PB cell donor contribution (CD45.1+ cells) was assessed 80 days after transplantation of CD45.1 donor cells into Plg+/+ or
Plg/ recipient mice. (A–C) Error bars represent SEM. Survival of Plg/ recipient mice ([D], n = 10) and Plg+/+ recipient mice ([E], n = 9) wasmonitored
daily.
(F and G) Lethally irradiated Plg+/+ or Plg/ mice were transplanted with BM cells from donor Plg+/+ or Plg/ mice 16 days prior to 5-FU injection
(n = 9 in each group). After cell engraftment, a single dose of 5-FU was injected on day 0. (F) Survival of transplanted mice was monitored (*p < 0.05,
comparing survival of Plg+/+ recipient mice to Plg/ recipient animals). (G) Blood was drawn after 5-FU administration. Plasma samples were
analyzed for KitL by ELISA (n = 3). Error bars represent SEM.
(H) Immunohistochemical staining for fibrin (green fluorescence) in BM sections from Plg+/+ and Plg/mice treated with a single injection of 5-FU i.v.
(I) PA-mediated activation of Plg generates plasmin after induction of hematopoietic stress within the BM. Plasmin in turn can activate MMPs, espe-
cially MMP-9, thereby releasing chemo/cytokines, like KitL. These factors can regulate the hematopoietic stress response by promoting HSPC
proliferation, differentiation, and BM reconstitution. *p < 0.05.of HSPCs within the Plg-deficient BM stromal compart-
ment was due to reduced production of KitL. Lower KitL
levels were detected in Plg/ recipient chimeric mice as
compared to Plg+/+ recipient controls (Figure 6G). These
data underscore the importance of KitL release andmaybe
other yet-to-be-defined factors from BM stromal cells in
a Plg-competent environment for BM reconstitution after
myelosuppression with 5-FU.
Binding of Plg to fibrin enhances Plg activation (Camiolo
et al., 1971). Immunohistochemical staining of BM sec-
tions from WT animals after myelosuppression revealed666 Cell Stem Cell 1, 658–670, December 2007 ª2007 Elseviethat, during the hematopoietic regeneration phase, fibrin
was found in close vicinity of bone-lining osteoblasts
and later in vascular areas, which might be part of the re-
cently proposed vascular niche (Figure 6H) (Heissig et al.,
2005a). Fibrin deposition was observed in BM of Plg/
and, to a lesser extent, Plg+/+ mice aftermyelosuppressive
stress.
Our data indicate that activation of Plg in the regenera-
tion phase after myelosuppression results in an orderly ac-
tivationof anotherproteasecascade, likeMMPs (Figure 6I).
This proteolytic mixture helps to make growth factorsr Inc.
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hematopoietic cell proliferation and differentiation.
DISCUSSION
The cellular BM microenvironment mediates the stem cell
choice of self-renewal versus differentiation. Whereas
self-renewal is important to maintain the stem cell pool,
rapid recruitment of HSCs into cell cycle followed by pro-
liferation, and differentiation allows the organism to adapt
to hematopoietic stress—cell loss after blood loss or mye-
losuppression—with the formation of new blood cells. In
this study, we provide genetic, functional, and biochemi-
cal evidence that the orderly activation of two separate
protease systems, the Plg/PA fibrinolytic system and the
MMP system after hematopoietic stress, allows hemato-
poietic cell proliferation and differentiation to take place,
a process in part mediated by the release of KitL (Fig-
ure 6I). Collectively, these data introduce a novel para-
digm by which fibrinolytic enzymes mediate systemic
and localized effects in the BM and establish a novel
role for Plg activation in hematopoiesis.
Local Accumulation of Components
of the Plasminogen System within the BM
We found local accumulation of Plg/plasmin within the BM
stromal compartment after myelosuppression and dem-
onstrated endogenous tPA expression within BM stromal
and hematopoietic cells. The presence of fibrinolytic fac-
tors within the BM in vivo suggests that localized proteol-
ysis occurs during BM cell reconstitution.
Plasmin Activates MMP-9 in the BM
Butwhat is the function of proteolysis in stress hematopoi-
esis, and what are its mediators? Plasmin can cleave
proMMPs (MMP-9, MMP-12, MMP-1) (Lijnen et al.,
1998a). Here, we show that tPA either provided by BM
cells or exogenously administered causes MMP activa-
tion, namely MMP-2 and MMP-9 in cultured BM stromal
cells. MMPs have been identified as downstream targets
for plasmin activation in other cells, e.g., at the nerve injury
site (Zou et al., 2006).
The Fibrinolytic Factor tPA Modulates
Hematopoiesis by Releasing KitL
KitL is a growth factor for primitive hematopoietic cells and
multiple differentiating lineages, acting in synergy with
other cytokines to promote cell proliferation and differen-
tiation. KitL is synthesized as a transmembrane protein
that may be processed to produce soluble KitL (Huang
et al., 1990). We demonstrated that MMP-9 activation
can promote the shedding of KitL (Heissig et al., 2002).
Here, we show that tPA indirectly via Plg andMMP activa-
tion is able to release KitL from stromal cells.
Exogenous administration of recombinant tPA pro-
motesmyeloid, erythroid, andmegakyaryocytic cell differ-
entiation and progenitor proliferation. The importance of
KitL for these tPA-mediated effects on hematopoiesis
was supported by experiments using Sl/Sld mice, whereCell SttPA-mediated BM cell and progenitor proliferation did
not occur. Similarly, impaired BM regeneration seen in
Plg/ mice was due to an impaired compensatory
increase in KitL after myelosuppression, as administration
of KitL induced BM reconstitution and rescued Plg-
deficient mice.
Plg activation can occur via tPA, uPA, and plasma kalli-
krein (Lund et al., 2006) and has been implicated in cell
differentiation, like myoblast fusion and differentiation
(Suelves et al., 2002) or adipocyte differentiation (Selvara-
jan et al., 2001).
Rebleeding has been reported after tPA treatment in
ischemic stroke patients (Cheng et al., 2006), which could
stimulate HSPC proliferation (Hellman and Grate, 1967).
Therefore, it is conceivable that bleeding could have
affected the outcome of our study. But no bleeding was
observed after tPA administration into healthy, nonische-
mic mice. tPA-mediated progenitor proliferation was
also observed in vitro, where bleeding can be excluded.
tPA-Mediated Effects on Hematopoietic Cells
Require a Functional Microenvironment
KitL expressed in the stromal compartment is a key factor
to maintain hematopoiesis. We observed reduced
engraftment of either Plg/ or Plg+/+ HSPCs into Plg/
recipient mice, which was not due to impaired HSPC
adhesion (data not shown) but due to a BMmicroenviron-
ment, which could not provide KitL to support long-term
hematopoiesis. The effects of a defective microenviron-
ment are best known from studies on Sl/Sld mice. When
cells had been transplanted very early into a non-KitL
defective environment, long-term repopulating activity
was identical in Sl/Sld andWTmice (Barker, 1997). Persis-
tence of HSCs in a defective environment resulted in
progressive loss of HSC activity (Barker, 1994).
Similar to Sl/Sld mice, Plg/ mice showed reduced
numbers of hematopoietic progenitors, whereas the
HSC compartment (cells with long-term repopulating
capacity) was functionally normal. Our data indicate that
Plg plays a role in cell differentiation and progenitor prolif-
eration rather than HSC-associated self-renewal. There-
fore, myelosuppressionmodels can reveal the hematopoi-
etic phenotype. The early death observed in Plg/ mice
after myelosuppression is most likely due to lack of cell
differentiation and progenitor proliferation, as differenti-
ated cells rather than HSCs ensure hematopoietic recov-
ery and survival 10 days after injection of the myelosup-
pressive agent. Further studies will show if, aside from
KitL, other growth factors are altered in Plg/ mice.
This study has implications for the control of various dis-
eases. Plg activation is associated with cancer invasion
and metastasis (Andreasen et al., 2000). It is possible
that plasmin generated in tumors activates MMPs and
releases KitL, a process that could promote metastasis
or angiogenesis (Kijima et al., 2002; Heissig et al., 2003).
Further studies will be necessary to evaluate this. tPA is
in clinical use in the treatment of myocardial infarction
(Andersen et al., 2003; Wilcox, 1996). Its positive effect
on myocardial reperfusion had been thought to be dueem Cell 1, 658–670, December 2007 ª2007 Elsevier Inc. 667
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fects after myocardial infarction is driven by KitL and its ef-
fect on hematopoietic cells. Finally, tPA can potentially be
used for stem cell harvesting andmight be used to expand
HSPCs.
Conclusions
Activation of Plg after hematopoietic stress (Figure 6I)
leads to activation of another protease cascade, namely
MMPs. Activation of MMP-9 releases, e.g., KitL, which
in turn controls hematopoietic cell proliferation and differ-
entiation. This process helps to replenish hematopoietic
cells within the BM. The involvement of the fibrinolytic
system in the regulation of adult stress hematopoiesis





Age- (6–8 week) and sex-matched Plg+/+ and Plg/ mice were
obtained by heterozygous breeding of mice backcrossed into a
C57BL/6J background (Bugge et al., 1995). MMP-9+/+ and MMP-9/
mice were used after more than ten backcrosses into CD1 mice (Heis-
sig et al., 2002). Animal procedures were approved by the Animal Care
Committee of Juntendo University. KitL WT (WBB6F1) and KitL-defi-
cient (Sl/Sld), CD45.1 congenic, and C57BL/6 mice were purchased
from SLC (Japan).
Myelosuppression Model
Plg+/+ and Plg/mice,MMP-9+/+ andMMP-9/mice, or Plg chimeric
mice were injected with the myelosuppressive agent 5-FU (250 mg/kg
body weight, Kyowa Hakko Kogyo, Tokyo, Japan). Survival was
monitored daily.
Chimeric BM Transplantation Model
Plg+/+ or Plg/ animals were lethally irradiated (900 cGy) and 6 hr later
underwent transplantation with 2 3 107 BMMCs from either Plg+/+ or
Plg/ animals.
Competitive Transplantation Experiments
Lethally irradiated Ly-5.1 mice were injected with 10, 50, or 100 KSL
cells (ten recipient mice per cell concentration) from Plg+/+ and Plg/
mice together with 53 104 CD45.1 BM competitor cells. Percentage of
donor-derived three-lineage contribution in PBMCs using antibodies
against CD45.2, Gr-1, B220, or CD3 was assessed.
Long-Term Engraftment
1 3 105, 4 3 104 or 2.5 3 104 BM cells from Plg+/+ or Plg/ mice
(CD45.2+; six mice each) were transplanted into lethally irradiated
(900 cGy) CD45.1 syngenic mice together with a constant number of
competitor cells (5 3 105). In another experiment, 1 3 105, 4 3 104,
or 2.53 104 CD45.1+ BM cells together with 53 105 CD45.1 compet-
itors were transplanted into lethally irradiated congenic Plg+/+ or Plg/
(CD45.2+) recipient mice. The percent of donor contribution was
calculated by measuring CD45.1+ and CD45.2+ on PB leukocytes in
recipient mice 90 days posttransplant.
tPA Administration In Vivo
Mice were injected with human recombinant tPA (kindly provided by
Eisai, Tokyo, Japan) intraperitoneally at a concentration of 1.25 3
106 IU = 1 mg/kg body weight daily or PBS for a total of 3 days. (Rec-
ommended tPA dosage in humans for clinical use is 10 mg/kg.) Blood
and plasma samples were collected.668 Cell Stem Cell 1, 658–670, December 2007 ª2007 ElsevierPeripheral Blood Analysis
Blood was collected frommice by retro-orbital bleeding using heparin-
ized capillaries. WBC counts were determined. PBMCs were isolated
from heparinized blood after centrifugation over a discontinuous
gradient using lympholyte-M (Cedarlane, Ontario, Canada). Plasma
samples were stored at 80C until further analysis.
CFU-S Assay
Mobilized PBMCs were obtained and subjected to a CFU-S assay as
previously described (Hattori et al., 2001). Mice were sacrificed on
day 8. The number of visible colonies was counted.
Histological Assessment
Deparaffinized BM sections (3–5 mm) were stained for fibrin(ogen) fol-
lowed by a secondary Alexa 488-labeled antibody (Molecular Probes,
Inc) or with hematoxylin and eosin (H&E). BM sections were stained for
MMP-9 (7-11C) as described (Heissig et al., 2002). BM sections were
pretreated with hyaluronidase (for Plg) or Proteinase K (for tPA),
blocked, and incubated with a rabbit anti-human Plg polyclonal Ab
(H-90, Santa Cruz, dilution 1/100) or rabbit anti-human tPA IgG fraction
(INR, dilution 1/100) for 1 hr. Following a catalyzed signal amplification




Murine BM cells were obtained after flushing their femurs and tibiae.
Cells were stained using a lin cell separation kit (Stem Cell Technol-
ogies, Vancouver). After running through two MACS columns (Miltenyi
Biotec), more than 90% of the separated lin cells were c-Kit/Sca-1
double-positive cells by FACS.
Hematopoietic Progenitor Assay
PBMCs (105 cells/plate) or lin cells (53 103 cells/plate) were plated in
triplicate in 1 ml of a commercially available methylcellulose-based
assay (Methocult, Stem Cell Technologies, Vancouver).
Culture Supernatants
(1) BM cells (1 3 106) from 5-FU treated Plg+/+ and Plg/ mice were
cultured overnight in serum-free medium. (2) MS-5 cells were grown
to confluency in 6-well plates (Falcon) and then exposed overnight in
serum-free medium to tPA (5 mg/ml CleactorR). (3) BM-derived lin+
cells (1 3 105) from Plg+/+ mice were cultured in serum-free medium
overnight with or without recombinant tPA (5 mg/ml, CleactorR). Culture
supernatants were collected. Supernatants (1–3) were analyzed by
substrate zymography or ELISA. Or confluent MS-5 cells or primary
stromal cells were cultured in the presence of tPA (5 mg/ml, CleactorR)
with or without PAI-1 (2 mg/ml, Calbiochem) or MMP inhibitor (CGS
27023A, Novartis, Basel, Switzerland, 1 nM daily). Supernatants
were stored at 30C and analyzed for the release of KitL by ELISA.
Stromal-Based Expansion Cultures
1 3 105 lin cells from BM of Plg+/+ mice were cocultured with a con-
fluent layer of stromal cells (MS-5). Recombinant tPA (5 mg/ml, daily,
CleactorR) was added to cultures with or without KitL (2 mg/ml, every
other day). Seven days later, adherent cells were retrieved using tryp-
sin (Sigma) and pooled with the nonadherent cells. Hematopoietic cells
were counted and subjected to a progenitor assay.
Suspension Culture
BM-derived lin cells (1.0 3 105) from Plg+/+ mice were cultured in
serum-free medium for 4 days in the presence/absence of recombi-
nant tPA (1 or 5 mg/ml, CleactorR, Eisai Co, Japan) plus or minus re-
combinant KitL (2 mg/ml, PeproTech) daily added to the cultures. Cells
were harvested, counted, and subjected to a progenitor cell assay.
Proliferation Blocking Experiment
Lin cells (1.2 3 105) were isolated from the BM of Plg+/+ mice and
cocultured with MS-5 stromal cells in the presence/absence of
recombinant tPA (5 ug/ml, CleactorR) with or without blocking anti-
bodies against c-Kit (clone ASK, final concentration 0.5 mg/ml), against
SCF (KitL, final concentration 0.5 mg/ml, R & D Systems), with or with-
out PAI-1 (2 mg/ml, Calbiochem), or the MMP inhibitor (1 nM, CGSInc.
Cell Stem Cell
Fibrinolytic System Regulates Hematopoiesis27023A, Novartis, Basel, Switzerland) daily. The adherent and nonad-
herent cells collected after 5 days of culture. After counting, hemato-
poietic cells were subjected to a hematopoietic progenitor assay.
Substrate Zymography
Supernatants were treated with gelatin-agarose beads and processed
through sodium dodecyl sulfate polyacrylamide gel electrophoresis as
described (Heissig et al., 2002) A pro-MMP-2 standard (Oncogene
Research Products, Cambridge, MA) was used to determine the
molecular weight of gelatinolytic bands.
RNA Extraction and RT-PCR Analysis
Total RNAs were extracted from 4-week-old LTC stroma and MS-5
cells using Trizol reagent. RT-PCR was performed using One Step
RNA PCR Kit (AMC) (TaKaRa Shuzo Co., Japan). b-actin primers 50-
TGGAATCCTGTGGCATCCATGAAAC-30 (sense strand) and 50-TAAAA
CGCAGCTCAGTAACAGTCCG-30 (antisense strand) were used to test
the integrity of the total RNA extracted (349 bp product). Primer
sequences for tPA were 50-CTGAGGTCACAGTCCAAGCAATGT-30
(sense primer) and 50-GCTCACGAAGATGATGGTGTAAAGA-30 (anti-
sense), yielding a 564 bp product. Primer sequences for plasminogen
were 50-TGTGGGCTCTAAAGATGGAACTCC-30 (sense primer) and 50-
GACAAGGGGACTCGCTGGATGGCTA-30 (antisense primer), yielding
a product of 268 bp.
FACS Analysis
BM cells of Plg+/+ and Plg/ mice were incubated with CD11b-FITC
and Gr-1-PE antibodies and analyzed by FACS. BM cell ploidy was
analyzed using FACS after cell fixation with ethanol and labeling with
propidium iodide (PI). For cell-cycle analysis, whole BM cells were
labeled with Sca-1-FITC and stained with PI (Molecular Probes, OR)
as described (Heissig et al., 2002).
BM cells of untreated and tPA-treated Plg+/+ mice were stained with
CD11b-FITC and Gr-1-PE or CD71-FITC and Ter119-PE antibodies
and analyzed by FACS. Next, lin BM cells were stained with Sca-1-
FITC and PI before cell-cycle analysis was performed. For SP cell anal-
ysis, BM cells were subjected to FACS (BD Biosciences) by using the
MoFlo (DakoCytomation) with the following filter sets: 405/30 band-
pass (BP) to detect Hoechst blue, 585/42 BP to detect Hoechst red,
and a 440 nm long-pass dichromic filter to separate Hoechst red
from Hoechst blue. A subset of cells treated with verapamil confirmed
the identity of the SP gate.
Immunoassay for KitL, proMMP-9, and Active MMP-9
In plasma or culture supernatants, KitL (SCF) was measured using
commercially available ELISA (R & D Systems). Active MMP-9 was
analyzed using the MMP-9 Activity Assay Biotrak System ELISA
(Amersham Biosciences, UK).
Statistical Analysis
Results are expressed as mean ± SEM (standard error of mean). Data
were analyzed using the unpaired two-tailed Student’s t test. P values
of <0.05 were considered significant.
Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.cellstemcell.com/cgi/content/full/1/6/
658/DC1/.
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